Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beloranib in Obese Subjects
NCT01666691Phase 2Completed
- Sponsor
- Zafgen, Inc.
- Start
- Aug 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of beloranib in obesity (6 arms), sponsored by Zafgen, Inc. Primary endpoints: Safety and tolerability at 26 weeks, Weight loss at 13 weeks and 1 more. Started Aug 2012; status: completed.
02
Drugs
beloranib
03
Conditions
obesity
Beyond the preview
Go deeper on NCT01666691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666691.